Group 1 - The ETF market showed mixed performance on the 7th, with the medical device ETF (159797) leading gains at 2.24% [2] - The Sci-Tech chip design ETF (588780) also saw an increase of 2.11%, along with the medical device index ETF (159898) which rose by 2.11% [2] - Conversely, the N-Hong Kong Stock Connect innovative drug ETF by Jiashi (520970) experienced the largest decline at 3.04%, followed by the Sci-Tech innovative drug ETF by Guotai (589720) which fell by 2.96%, and the Hong Kong Stock Connect innovative drug ETF by ICBC (159217) which dropped by 2.93% [2]

Group 1 - The Hong Kong Stock Connect Innovative Drug ETF (工银, 159217) experienced a decline of 0.26% on August 4, with a trading volume of 845 million yuan [1] - The fund's shares decreased by 19 million to a total of 3.504 billion shares, with a reduction of 291 million shares over the last 20 trading days [1] - The latest net asset value of the fund is calculated at 5.355 billion yuan [1] Group 2 - The performance benchmark for the Hong Kong Stock Connect Innovative Drug ETF is the adjusted return of the National Index for Hong Kong Stock Connect Innovative Drugs [1] - The fund is managed by ICBC Credit Suisse Asset Management Company, with fund managers Liu Weilin and Jiao Wenlong [1] - Since its establishment on March 26, 2025, the fund has achieved a return of 52.81%, with a one-month return of 16.12% [1]

Group 1 - The core viewpoint of the news highlights the strong performance of the Hong Kong Stock Connect Innovative Drug ETF, which has achieved a 68.7% increase over the past year, ranking first among similar indices [1][3] - The ETF has seen significant trading activity, with a recent trading volume of 572 million yuan and a turnover rate of 14.22%, indicating high liquidity [1] - The upcoming 2025 American Society of Clinical Oncology (ASCO) annual meeting is expected to showcase significant advancements in cancer treatment, with a focus on innovative therapies [1][2] Group 2 - Chinese innovative drug companies are gaining international recognition, with a record number of 71 original research results presented at the ASCO meeting, indicating a growing global presence [2] - The ASCO meeting is anticipated to further update clinical data and reports, potentially increasing interest in innovative drugs [2] - The positive cycle of innovation, commercialization, and reinvestment in research is being validated, with expectations that "License out + equity cooperation" will become mainstream for international expansion [2] Group 3 - The National Index for Hong Kong Stock Connect Innovative Drugs has a low price-to-earnings ratio of 27.25, indicating a favorable valuation position [3] - The index's constituent stocks are heavily concentrated in the biopharmaceutical and chemical drug sectors, which together account for 94.2% of the index [3] - The ETF has the lowest fee rate among similar products, which reduces holding costs and enhances liquidity through T+0 trading [3]